2024
BK polyomavirus DNAemia, allograft rejection, and de novo donor‐specific antibodies after lowering target tacrolimus levels in pediatric kidney transplant recipients
Huang H, Xiang Y, George R, Winterberg P, Serluco A, Liverman R, Yildirim I, Garro R. BK polyomavirus DNAemia, allograft rejection, and de novo donor‐specific antibodies after lowering target tacrolimus levels in pediatric kidney transplant recipients. Pediatric Transplantation 2024, 28: e14791. PMID: 38808701, DOI: 10.1111/petr.14791.Peer-Reviewed Original ResearchConceptsDe novo donor-specific antibodiesTarget tacrolimus levelsDevelopment of de novo donor-specific antibodiesBiopsy-proven rejectionDonor-specific antibodiesMonths post-KTTacrolimus levelsTime of transplantationPediatric KT recipientsBK polyomavirusBKV-DNAemiaPost-KTPost-intervention cohortAllograft rejectionRecipient ageKT recipientsKidney transplantationPediatric kidney transplant recipientsLow tacrolimus levelsReduction of immunosuppressionKaplan-Meier survival analysisYounger recipient ageIndividualized immunosuppressive regimensKidney transplant recipientsRetrospective chart review
2023
Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis
Liverman R, Serluco A, Nance G, George R, Rodriguez D, Deshpande S, Mao C, Garro R, Yildirim I. Incidence of cytomegalovirus DNAemia in pediatric kidney, liver, and heart transplant recipients: Efficacy and risk factors associated with failure of weight‐based dosed valganciclovir prophylaxis. Pediatric Transplantation 2023, 27: e14493. PMID: 36945819, DOI: 10.1111/petr.14493.Peer-Reviewed Original ResearchConceptsSolid organ transplant recipientsPediatric solid organ transplant recipientsCytomegalovirus DNAemiaValganciclovir prophylaxisDose reductionRisk factorsTransplant recipientsImpact of dose adjustmentsRisk factors associated with failureFactors associated with failureOrgan transplant recipientsHeart transplant recipientsIndependent risk factorRetrospective cohort studyAssociated with morbidityCMV DNAemiaCytomegalovirus eventsValganciclovir dosingImmunosuppressive therapyDose adjustmentYounger age groupsDNAemiaValganciclovirRisk stratificationAdverse events
2021
Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019.
Yee ME, Lai KW, Bakshi N, Grossman JK, Jaggi P, Mallis A, Wang YF, Jerris RC, Lane PA, Yildirim I. Bloodstream Infections in Children With Sickle Cell Disease: 2010-2019. Pediatrics 2021, 149 PMID: 34913059, PMCID: PMC8959248, DOI: 10.1542/peds.2021-051892.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnemia, Sickle CellChildFemaleGenotypeGeorgiaHumansIncidenceMaleRetrospective StudiesRisk FactorsSepsisConceptsSickle cell diseaseBloodstream infectionsBlood culturesSickle cell anemia genotypesRetrospective cohort studyInvasive bacterial infectionsMultivariate logistic regressionConfidence intervalsAverage incidence rateSpectrum of pathogensAntibiotic prophylaxisEligible patientsFunctional aspleniaBSI episodesCohort studyChronic transfusionMedian ageAnnual incidenceOverall incidenceRisk factorsIncidence rateCell diseaseEmpirical treatmentBordetella holmesiiCommon pathogensImpact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
Lucas C, Vogels CBF, Yildirim I, Rothman JE, Lu P, Monteiro V, Gehlhausen JR, Campbell M, Silva J, Tabachnikova A, Peña-Hernandez MA, Muenker MC, Breban MI, Fauver JR, Mohanty S, Huang J, Shaw A, Ko A, Omer S, Grubaugh N, Iwasaki A. Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. Nature 2021, 600: 523-529. PMID: 34634791, PMCID: PMC9348899, DOI: 10.1038/s41586-021-04085-y.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 variantsMRNA vaccine-induced immunityT-cell activation markersSARS-CoV-2 antibodiesSecond vaccine doseVaccine-induced immunityCell activation markersT cell responsesHigh antibody titresSARS-CoV-2Vaccine boosterVaccine doseActivation markersVaccine dosesHumoral immunityAntibody titresMRNA vaccinesVitro stimulationNeutralization capacityNeutralization responseCell responsesE484KNucleocapsid peptideAntibody-binding sitesGreater reductionA Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Hospitalizations in Children
Yildirim I, Kao CM, Tippett A, Suntarattiwong P, Munye M, Yi J, Elmontser M, Quincer E, Focht C, Watson N, Bilen H, Baker JM, Lopman B, Hogenesch E, Rostad CA, Anderson EJ. A Retrospective Test-Negative Case-Control Study to Evaluate Influenza Vaccine Effectiveness in Preventing Hospitalizations in Children. Clinical Infectious Diseases 2021, 73: 1759-1767. PMID: 34410341, PMCID: PMC8599178, DOI: 10.1093/cid/ciab709.Peer-Reviewed Original ResearchConceptsInfluenza vaccine effectivenessInfluenza-positive casesInfluenza-related hospitalizationsVaccine effectivenessInfluenza seasonOdds ratioInfluenza ALaboratory-confirmed influenza-related hospitalizationsTest-negative case-control study designAdjusted vaccine effectivenessInfluenza-negative controlsTest-negative controlsCase-control study designHospitalization of childrenTest-negative casesConfidence intervalsNon-Hispanic blacksLogistic regression modelsPreventing HospitalizationInfluenza vaccinationInfluenza burdenMedian ageInfluenza B.Influenza infectionPediatric hospitalizationsClinical Epidemiology and Outcomes of Pediatric Musculoskeletal Infections
Yi J, Wood JB, Creech CB, Williams D, Jimenez-Truque N, Yildirim I, Sederdahl B, Daugherty M, Hussaini L, Munye M, Tomashek KM, Focht C, Watson N, Anderson EJ, Thomsen I. Clinical Epidemiology and Outcomes of Pediatric Musculoskeletal Infections. The Journal Of Pediatrics 2021, 234: 236-244.e2. PMID: 33771580, PMCID: PMC8238832, DOI: 10.1016/j.jpeds.2021.03.028.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdministration, OralAdolescentAnti-Bacterial AgentsArthritis, InfectiousChildChild, PreschoolCombined Modality TherapyFemaleGram-Negative Bacterial InfectionsGram-Positive Bacterial InfectionsHumansInfantLogistic ModelsMaleMethicillin-Resistant Staphylococcus aureusOrthopedic ProceduresOsteomyelitisRetrospective StudiesStaphylococcal InfectionsTreatment OutcomeUnited StatesConceptsOsteomyelitis/septic arthritisAcute hematogenous osteomyelitisMethicillin-resistant S aureusSeptic arthritisHematogenous osteomyelitisTreatment failureS aureusOral therapyAntibiotic therapyMusculoskeletal infectionsHigher oddsPediatric musculoskeletal infectionsLonger hospital stayOral antibiotic therapyRetrospective cohort studyTreatment-related complicationsTreatment-associated complicationsHospital stayPediatric infectionsCohort studyParenteral therapyTreatment complicationsIntensive careRecurrent infectionsWorse outcomes
2020
Vaccine‐induced protection against hepatitis B in pediatric solid organ transplant patients
Ball M, Liverman R, Serluco A, Yildirim I. Vaccine‐induced protection against hepatitis B in pediatric solid organ transplant patients. Pediatric Transplantation 2020, 25: e13920. PMID: 33217081, DOI: 10.1111/petr.13920.Peer-Reviewed Original ResearchConceptsVaccine-induced protectionPediatric solid organ transplant patientsSolid organ transplant patientsOrgan transplant patientsHepatitis B virusHBV vaccinationTransplant patientsHepatitis B surface antibody titerHBV vaccination coverageHBV vaccine seriesPediatric SOT recipientsDetailed chart reviewYears of ageHBsAb titersSeroprotection ratesSOT recipientsHBV infectionTransplanted childrenVaccine seriesChart reviewHepatitis BLaboratory featuresImmunogenicity dataVaccination coverageVaccine immunityRecognition and Outcomes of Pneumococcal Meningitis in 2 Tertiary Pediatric Hospitals Since the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine
Stevens JP, Lively A, Jerris R, Yildirim I, Lantis P. Recognition and Outcomes of Pneumococcal Meningitis in 2 Tertiary Pediatric Hospitals Since the Introduction of the 13-Valent Pneumococcal Conjugate Vaccine. Pediatric Emergency Care 2020, 38: e354-e359. PMID: 33181795, DOI: 10.1097/pec.0000000000002288.Peer-Reviewed Original ResearchConceptsPneumococcal conjugate vaccineLumbar puncturePneumococcal meningitisConjugate vaccineMeningeal signsLow suspicionMental statusPositive cerebrospinal fluid culturesLonger hospital lengthStreptococcus pneumoniae meningitisCerebrospinal fluid culturesCranial nerve palsyHours of admissionTertiary pediatric hospitalPoor clinical outcomeTertiary healthcare systemPneumococcal meningitis casesPneumococcal immunizationPneumoniae meningitisHospital lengthNerve palsyPrimary outcomeAntibiotic administrationClinical outcomesPediatric hospitalThe burden of respiratory syncytial virus infections among children with sickle cell disease
Rostad CA, Maillis AN, Lai K, Bakshi N, Jerris RC, Lane PA, Yee ME, Yildirim I. The burden of respiratory syncytial virus infections among children with sickle cell disease. Pediatric Blood & Cancer 2020, 68: e28759. PMID: 33034160, PMCID: PMC8246443, DOI: 10.1002/pbc.28759.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusSickle cell diseaseRespiratory viral panelRSV-positive casesRSV infectionAnnual incidenceHospitalization ratesCell diseaseBurden of RSVPediatric lower respiratory tract infectionsLaboratory-confirmed RSV infectionRespiratory syncytial virus infectionRSV-related hospitalization rateLower respiratory tract infectionsRSV positive testRSV-negative childrenRSV-negative patientsAcute chest syndromeSyncytial virus infectionRespiratory tract infectionsAverage annual incidenceMultivariate logistic regressionConfidence intervalsCase-control studyOutcome of childrenMicrobiology and radiographic features of osteomyelitis in children and adolescents with sickle cell disease
Kao CM, Yee ME, Maillis A, Lai K, Bakshi N, Rostad BS, Jerris RC, Lane PA, Yildirim I. Microbiology and radiographic features of osteomyelitis in children and adolescents with sickle cell disease. Pediatric Blood & Cancer 2020, 67: e28517. PMID: 32710705, PMCID: PMC8369475, DOI: 10.1002/pbc.28517.Peer-Reviewed Original ResearchConceptsSickle cell diseaseMethicillin-susceptible Staphylococcus aureusMagnetic resonance imagingAntibiotic treatmentOperative culturesCell diseaseLarge tertiary pediatric centerPrescribed antibiotic treatmentTertiary pediatric centerCulture-positive casesKey presenting symptomsChildren ages 6Bone painMicrobiologic etiologyPresenting symptomPediatric centersBone infarctsMedical chartsMicrobiologic findingsRadiographic featuresImaging featuresOsteomyelitisProbable osteomyelitisDiagnostic codingTissue debridementInitial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole
Bernardo V, Miles A, Fernandez AJ, Liverman R, Tippett A, Yildirim I. Initial posaconazole dosing to achieve therapeutic serum posaconazole concentrations among children, adolescents, and young adults receiving delayed‐release tablet and intravenous posaconazole. Pediatric Transplantation 2020, 24: e13777. PMID: 32639095, DOI: 10.1111/petr.13777.Peer-Reviewed Original ResearchConceptsYears of ageMedian daily doseTrough concentrationsDaily dosePlasma concentrationsYoung adultsPlasma trough concentrationsSerum posaconazole concentrationsInvasive fungal diseaseTherapeutic plasma concentrationsDelayed-release tabletsIntravenous posaconazolePosaconazole dosingImmunocompromised childrenPatients 13Optimal dosingBroad-spectrum antifungalsAdolescent patientsPosaconazole concentrationsHigher dosingPatientsBody weightGrade 1ProphylaxisDosingBrincidofovir for the treatment of human adenovirus infection in pediatric solid organ transplant recipients: A case series
Londeree J, Winterberg PD, Garro R, George RP, Shin S, Liverman R, Serluco A, Romero R, Yildirim I. Brincidofovir for the treatment of human adenovirus infection in pediatric solid organ transplant recipients: A case series. Pediatric Transplantation 2020, 24: e13769. PMID: 32558134, DOI: 10.1111/petr.13769.Peer-Reviewed Original ResearchConceptsPediatric SOT recipientsSOT recipientsCase seriesSevere diseasePediatric solid organ transplant recipientsSolid organ transplant recipientsType of allograftMainstay of treatmentOrgan transplant recipientsSeverity of diseaseHuman adenovirus infectionHAdV diseaseHAdV viremiaPediatric recipientsTransplant recipientsHAdV infectionDisease courseAntiviral therapySignificant morbidityDisease presentationUS FDAAdenovirus infectionBrincidofovirDiseaseRecipients
2019
Cryptosporidiosis among solid organ transplant recipient attendees at a summer camp
McAteer J, Jernigan S, Mao C, Gonzalez MD, Watson RJ, Liverman R, Angelo M, M. H, Shane A, Yildirim I. Cryptosporidiosis among solid organ transplant recipient attendees at a summer camp. Pediatric Transplantation 2019, 24: e13649. PMID: 31885132, DOI: 10.1111/petr.13649.Peer-Reviewed Original ResearchConceptsTransplant recipientsSolid organ transplant recipientsKidney transplant recipientsRetrospective cohort studyOrgan transplant recipientsPediatric transplant recipientsOverall attack rateAcute rejection eventsLong-term interventionsImmunosuppressive therapySymptom durationCohort studyRisk factorsNotable burdenStool specimensCryptosporidiosis infectionEtiologic agentRejection eventsAttack rateFurther outbreaksInfectionRecipientsCryptosporidium hominisCryptosporidiosisOutbreak
2015
Vaccination, Underlying Comorbidities, and Risk of Invasive Pneumococcal Disease
Yildirim I, Shea KM, Little BA, Silverio AL, Pelton SI. Vaccination, Underlying Comorbidities, and Risk of Invasive Pneumococcal Disease. Pediatrics 2015, 135: 495-503. PMID: 25647674, DOI: 10.1542/peds.2014-2426.Peer-Reviewed Original ResearchMeSH KeywordsBacterial CapsulesChildChild, PreschoolComorbidityFemaleFollow-Up StudiesHumansIncidenceInfantMaleMassachusettsPneumococcal InfectionsPneumococcal VaccinesPopulation SurveillancePrognosisRetrospective StudiesRisk AssessmentRisk FactorsStreptococcus pneumoniaeVaccinationVaccines, ConjugateConceptsInvasive pneumococcal diseasePneumococcal diseaseUnderlying conditionOutcomes of IPDPrevention of IPDChildhood invasive pneumococcal diseasePneumococcal vaccination statusPolysaccharide pneumococcal vaccineYear of diagnosisPrimary care providersCase fatality rateChronic respiratory diseasesImmunocompromising conditionsIPD diagnosisUnderlying comorbiditiesImmunization PracticesIPD casesPneumococcal vaccineVaccination statusConjugate vaccineMassachusetts childrenClinical presentationSerotype distributionHigher hospitalizationClinical data
2010
Risks and outcome of fungal infection in neutropenic children with hematologic diseases.
Aytaç S, Yildirim I, Ceyhan M, Cetin M, Tuncer M, Kara A, Cengiz AB, Seçmeer G, Yetgin S. Risks and outcome of fungal infection in neutropenic children with hematologic diseases. The Turkish Journal Of Pediatrics 2010, 52: 121-5. PMID: 20560245.Peer-Reviewed Original ResearchConceptsFebrile neutropenic episodesAcute myeloid leukemiaNeutropenic episodesAcute lymphoblastic leukemiaAplastic anemiaAntifungal treatmentFungal infectionsMortality rateAmphotericin BNeutropenic childrenRetrospective studyLymphoblastic leukemiaMyeloid leukemiaHematologic diseasesTreatment groupsPatientsWhole groupInfectionEpisodesLeukemiaMortalityAnemiaGroupDiseaseFluconazole
2008
Cytomegalovirus hepatitis and ganciclovir treatment in immunocompetent children.
Tezer H, Seçmeer G, Kara A, Ceyhan M, Cengiz AB, Devrim I, Us D, Yüce A, Gürakan F, Yildirim I, Ozen H, Saltik-Temizel IN. Cytomegalovirus hepatitis and ganciclovir treatment in immunocompetent children. The Turkish Journal Of Pediatrics 2008, 50: 228-34. PMID: 18773667.Peer-Reviewed Original ResearchConceptsBiliary atresiaGanciclovir treatmentCauses of hepatitisCongenital CMV infectionExtrahepatic biliary atresiaSigns of infectionCMV hepatitisCholestatic hepatitisCMV infectionCytomegalovirus infectionImmunocompetent childrenStudy groupHepatitisPatientsGroup IIDemographic featuresGroup IInborn errorsInfectionAtresiaChildrenTreatmentGroupGenetic diseasesCMV